Market News

Aetna (AET)

Aetna said today that its third-quarter net income climbed 18 percent to $326.2 million, or 73 cents a share, from 277.3 or 58 cents per share. Revenue rose 9% to 8,704.4 million from 7,981.4 million.
Results beat analysts' forecasts.

Oct 29 · 11:03:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Mylan (MYL)

Mylan Laboratories said today it had a third-quarter net loss attributable to Mylan common shareholders of $40.02 million or $0.13 per share, compared to profit of $182.36 million or $0.47 per share in the same quarter last year. Total revenues for the quarter declined to $1.264 billion from $1.656 billion in the prior year quarter. .
Analysts had a consensus revenue estimate of $1.23 billion in revenue for the quarter.

Oct 29 · 9:33:00 AM · Source: Company News
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Amgen (AMGN)

A British charitable trust filed a patent infringement suit against Amgen and Wyeth on Wednesday over their blockbuster Enbrel drug, one of the world's best-selling treatments for rheumatoid arthritis.
The Mathilda and Terence Kennedy Institute of Rheumatology Trust asked a federal court in Delaware to grant royalty payments and damages from Wyeth and Amgen for infringing a patent for treating arthritis.

Oct 28 · 12:28:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

WellPoint Health Networks (WLP)

Wellpoint said that third quarter earnings of $730.2 million, or $1.53 a share, down from $820.7 million, or $1.60 a share, a year earlier. Revenue rose 3.1% to $15.43 billion
Company's CEO said the nation's largest health insurer by members remains confident about the outlook for the current quarter and expects net growth of more than 400,000 national members in January.

Oct 28 · 10:46:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Glaxosmithkline Plc (GSK)

Glaxosmithkline said its third quarter net income increased 30 percent to 1.34 billion pounds ($2.18 billion) from 1.03 billion pounds a year earlier. Third- quarter revenue advanced 15 percent to 6.76 billion pounds, from 5.88 billion pounds,
Revenues topped the 6.75 billion-pound analyst estimates.

Oct 28 · 10:17:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Abbott Labs (ABT)

A European regulatory body plans to examine whether certain cholesterol drugs have long-term clinical benefits and one potential outcome could be their withdrawal from the market if they come up short.
The review will have implications for Abbott Laboratories and the pharmaceutical unit of Solvay SA, which Abbott is in the process of acquiring for $6.6 billion. Abbott and Solvay co-market the drugs TriCor and Trilipix, which are in a category the European regulatory body will assess.

Oct 27 · 11:16:00 AM · Source: Easy Bourse
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

LCA-Vision (LCAV)

LCA-Vision Inc., a provider of laser vision correction services under the LasikPlus® brand, today announced a third quarter loss of $19.9 million, or $1.07 per share, compared with a net loss of $4.7 million, or $0.25 per share in the year prior period Revenue was $27.6 million compared with $37.4 million during the third quarter of last year.

Oct 27 · 9:40:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb CEO Jim Cornelius said the company has over $1.3 billion in its coffers to finance more deals with small drug developers.
That's despite it's recent buyout of Medarex for $2.1 billion. The company will "continue to aggressively pursue acquisitions, licensing deals and other partnerships," promised Cornelius.

Oct 23 · 12:31:00 PM · Source: Fierce Biotech
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next